AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 10.52 |
Market Cap | 886.75M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -0.52 |
PE Ratio (ttm) | -20.11 |
Forward PE | n/a |
Analyst | Buy |
Ask | 10.63 |
Volume | 1,490,003 |
Avg. Volume (20D) | 1,832,455 |
Open | 10.58 |
Previous Close | 10.55 |
Day's Range | 10.19 - 10.89 |
52-Week Range | 3.25 - 14.44 |
Beta | undefined |
About AVXL
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinica...
Analyst Forecast
According to 3 analyst ratings, the average rating for AVXL stock is "Buy." The 12-month stock price forecast is $46, which is an increase of 339.98% from the latest price.
2 weeks ago · seekingalpha.com
Anavex Life Sciences: Jumping In On-Time Ahead Early Alzheimer's DecisionAnavex Life Sciences' ANAVEX 2-73 shows promise in treating Alzheimer's, with strong efficacy in slowing cognitive and functional decline, and an attractive safety profile. The EMA has accepted ANAVEX...
3 weeks ago · seekingalpha.com
Anavex Life Sciences Corp. (AVXL) Q4 2024 Earnings Call TranscriptAnavex Life Sciences Corp. (NASDAQ:AVXL ) Q4 2024 Earnings Call Transcript December 23, 2024 8:30 AM ET Company Participants Clint Tomlinson - IR Christopher Missling - President and CEO Sandra Boenis...
1 month ago · https://www.marketscreener.com
North American Morning Briefing : Global Ad Shares -2-Lundin Mining Announces Sale to Boliden of its Neves-Corvo operation in Portugal and Zinkgruvan operation in Sweden for Up to $1.52 Billion: Lundin To Receive Upfront Cash Consideration of $1.37B Upon...
2 months ago · seekingalpha.com
Anavex Life Sciences: Weighing The Pros And Cons Of A Possible EU Approval ScenarioAnavex Life Sciences' stock surged on new Alzheimer's trial data, but the data's inconsistency raises concerns, making the company a Hold rating. Despite some promising cognitive results, the lack of ...